Texas Health Presbyterian Hospital Dallas
Texas Health Presbyterian Hospital Dallas was paid $5.33M by Medicaid between Sep 2019 and Dec 2024, across 113 billing codes. Its largest line is 99284, emergency room visit (serious) — 32% of everything it billed.
DALLAS, TX 75231
Next to other Ambulatory Surgical Clinic/Center providers in Texas
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Paid by month
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2019 | 345 | $30K | |
| 2020 | 7,947 | $683K | |
| 2021 | 37,879 | $1.46M | |
| 2022 | 39,616 | $1.37M | |
| 2023 | 32,724 | $1.22M | |
| 2024incomplete | 20,324 | $567K |
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 32% | 8,999 | 8,342 | $1.69M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 19% | 3,022 | 2,785 | $1.00M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 13% | 11,272 | 10,603 | $686K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 4.3% | 1,165 | 1,100 | $228K |
| 80053 | Comprehensive metabolic panel | 3.6% | 12,059 | 10,055 | $194K |
| 87631 | 3.0% | 1,439 | 1,389 | $158K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 2.3% | 14,608 | 11,850 | $124K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.3% | 2,399 | 2,187 | $124K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 2.3% | 4,189 | 3,652 | $122K |
| 70450 | Computed tomography, head or brain; without contrast material | 2.0% | 1,484 | 1,396 | $108K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 1.4% | 1,169 | 1,027 | $72K |
| 71045 | Radiologic examination, chest; single view | <1% | 2,400 | 2,189 | $52K |
101 more codes
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 3,862 | $51K |
| 76801 | <1% | 597 | $49K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 1,229 | $43K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 497 | $40K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 993 | $39K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 239 | $35K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 913 | $34K |
| 83880 | <1% | 1,164 | $29K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 655 | $28K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 414 | $27K |
| 84484 | <1% | 2,994 | $25K | |
| 81001 | <1% | 6,153 | $19K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 596 | $19K |
| 84703 | <1% | 2,976 | $15K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 95 | $15K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 181 | $13K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 3,835 | $13K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 2,116 | $11K |
| 93976 | <1% | 159 | $11K | |
| CP007 | <1% | 250 | $11K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 773 | $11K |
| 86850 | <1% | 560 | $9K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 547 | $9K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 82 | $9K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 2,397 | $9K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 293 | $9K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 680 | $8K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 1,985 | $8K |
| 84702 | <1% | 995 | $8K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 132 | $8K |
| 83690 | <1% | 2,243 | $8K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 155 | $8K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 732 | $7K |
| 94760 | <1% | 358 | $7K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 280 | $7K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 1,824 | $7K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 870 | $7K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 267 | $6K |
| 83605 | <1% | 726 | $6K | |
| 81025 | <1% | 821 | $6K | |
| 76830 | Ultrasound, transvaginal | <1% | 56 | $6K |
| 83735 | <1% | 1,359 | $5K | |
| 87634 | <1% | 80 | $5K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 15 | $5K |
| 87040 | <1% | 695 | $5K | |
| 85610 | <1% | 1,763 | $4K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 30 | $4K |
| 87430 | <1% | 230 | $3K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 809 | $3K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 2,165 | $3K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 520 | $3K |
| 85730 | <1% | 694 | $3K | |
| 85379 | <1% | 411 | $3K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 895 | $3K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 26 | $2K |
| 86901 | <1% | 1,117 | $2K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 3,270 | $2K |
| 86900 | <1% | 766 | $2K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 277 | $2K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 13 | $2K |
| 73560 | <1% | 36 | $1K | |
| 96376 | <1% | 430 | $1K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 12 | $1K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 1,012 | $1K |
| 84100 | <1% | 336 | $936.50 | |
| 86140 | <1% | 292 | $902.84 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 910 | $673.97 |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 24 | $658.71 |
| 85027 | <1% | 171 | $637.01 | |
| 73630 | <1% | 13 | $573.17 | |
| 81003 | <1% | 218 | $397.95 | |
| 84145 | <1% | 13 | $309.72 | |
| 82550 | <1% | 62 | $301.48 | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 34 | $263.32 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 250 | $253.83 |
| 82607 | <1% | 12 | $166.15 | |
| 80061 | Lipid panel | <1% | 15 | $138.20 |
| 82565 | <1% | 65 | $135.92 | |
| 85014 | <1% | 74 | $122.53 | |
| 87186 | <1% | 13 | $117.30 | |
| 36415 | Collection of venous blood by venipuncture | <1% | 3,619 | $107.36 |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 100 | $99.35 |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 48 | $98.03 |
| 86769 | <1% | 13 | $91.75 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 40 | $91.38 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 134 | $64.86 |
| 87210 | <1% | 14 | $59.37 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 52 | $53.07 |
| 85652 | <1% | 12 | $47.76 | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 66 | $33.95 |
| J2704 | Injection, propofol, 10 mg | <1% | 256 | $24.52 |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 43 | $13.28 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 359 | $11.85 |
| 80051 | <1% | 17 | $10.94 | |
| 84520 | <1% | 17 | $6.17 | |
| 82947 | <1% | 17 | $6.12 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 21 | $4.08 |
| J0692 | Injection, cefepime hydrochloride, 500 mg | <1% | 13 | $2.62 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 15 | $2.55 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | <1% | 41 | $1.95 |
| A9270 | Non-covered item or service | 0% | 3,912 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
Who's on the registration
| Provider | Location | Paid |
|---|---|---|
| Texas Health Harris Methodist Hospital Fort Worth | Fort Worth, TX | $13.83M |
| Texas Health Arlington Memorial Hospital | Arlington, TX | $8.23M |
| Texas Health Harris Methodist Hospital Southwest Fort Worth | Fort Worth, TX | $5.20M |
| Texas Health Presbyterian Hospital Kaufman | Kaufman, TX | $4.09M |
| Texas Health Presbyterian Hospital Denton | Denton, TX | $3.84M |
| Texas Health Harris Methodist Hospital Stephenville | Stephenville, TX | $3.69M |
| Texas Health Harris Methodist Hospital Hurst-Euless-Bedford | Bedford, TX | $3.57M |
| Texas Health Presbyterian Hospital Plano | Plano, TX | $2.32M |
| Texas Health Harris Methodist Hospital Cleburne | Cleburne, TX | $2.31M |
| Texas Health Harris Methodist Hospital Azle | Azle, TX | $2.14M |
| Texas Health Harris Methodist Hospital Alliance | Fort Worth, TX | $986K |
| Texas Health Presbyterian Hospital Allen | Allen, TX | $965K |
| Texas Health Hospital Frisco | Frisco, TX | $473K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.